Futures slip, bank earnings ahead, Powell to speak - what’s moving markets
Chief Scientific Officer of Rapport Therapeutics (NASDAQ:RAPP), David Bredt, sold a total of 8,500 shares of common stock on September 15, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The sales amounted to approximately $205,648. The timing of the sale coincides with RAPP’s strong recent performance, with the stock up nearly 17% in the past week. According to InvestingPro, the company currently maintains a GREAT financial health score.
The transactions involved two separate sales. The first sale involved 5,098 shares sold at a weighted average price of $23.8841, for a total value of $121,761. Prices for these shares ranged from $23.42 to $24.41. The second sale consisted of 3,402 shares at a weighted average price of $24.6583, totaling $83,887. The prices for these shares ranged from $24.42 to $24.90.
Following these transactions, Bredt directly owns 418,142 shares of Rapport Therapeutics .
The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 12, 2024.
In other recent news, Rapport Therapeutics has priced a $250 million public offering at $26 per share, aiming to generate significant gross proceeds. This move comes alongside the company’s announcement to grant underwriters a 30-day option to purchase additional shares. In analyst updates, Truist Securities initiated coverage on Rapport Therapeutics with a Buy rating and a $44 price target, highlighting the company’s focus on central nervous system treatments. H.C. Wainwright also raised its price target for Rapport Therapeutics to $34, maintaining a Buy rating after positive data from a study on focal onset seizures. Additionally, Stifel increased its price target to $56, citing strong efficacy results from a Phase 2a trial for the company’s epilepsy drug candidate. These developments indicate growing interest and positive sentiment among analysts towards Rapport Therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.